

Author Index to Volumes 24-26

- Abbas, M., 26:35
Ahkee, Sunket, 24:7
Alkhuja, S., 24:15
Altwegg, M., 24:121
Arabi, Y., 24:47; 26:35
Arranz-Caso, J.A., 24:161; 26:137
Authur, R.R., 24:1
Ayers, L.W., 26:43
- Badalamenti, J., 25:97
Bale, M.J., 24:109
Ballow, C.H., 24:129
Baquero, F., 26:53
Barnishan, J., 26:43
Barrett, M.S., 24:113; 25:107, 147
Barry, A.L., 26:23
Bell, J., 25:9
Bellei, N., 25:65
Beyer, J., 26:73
Biedenbach, D.J., 25:47
Blanco, I., 25:143
Blevins, L., 24:31
Bonilla, H.F., 25:127; 26:17
Bottone, E.J., 26:87
Bradley, S.F., 26:17
Brookings, E.S., 24:93
Brown, S.D., 26:23
Brueggemann, A.B., 26:39
Burczak, J.D., 24:71
Burton, P.H., 25:89
Buschelman, B.J., 24:109
Buser, J., 24:121
Bush, C.A., 24:165
- Campognone, P., 24:141
Cantón, R., 26:53
Caramello, P., 26:7
Carroll, K.C., 24:31
Castelo, A., 24:1
Catalano, M., 25:27
Chernowitz, A., 26:13
Chiu, C., 26:91
Choi, Y.J., 25:21
Clark, R.B., 24:145
Clarridge, J.E., 24:37
Claycomb, S., 26:13
Coffman, S., 26:63
Cohen, M.A., 25:53
Colaninno, P.M., 24:15, 155, 169
Cormican, M.G., 25:83, 107, 201
Coutant, C., 25:9
Craig, W.A., 25:213
Crane, L., 24:47
- D'Amato, R.F., 24:15
Davaro, R., 24:141
de Rafael, L., 26:53
DeBin, J.A., 26:91
Denis, F., 24:25
Depetris, G., 24:65
DeRobertis, J.M., 24:105
Dillard, S.C., 24:93
Dockrell, D.H., 26:133
- Doern, G.V., 24:141; 25:133, 137; 26:39
Dorigan, F.D., 24:105
Ducic, S., 24:61
Durepaire, N., 24:25
- Ebrahimzadeh, A., 26:87
Eliopoulos, G.M., 25:35
Erdem, I., 26:79
Ernst, M.E., 26:125
Erwin, M.E., 24:87, 155, 169
Eto, S., 24:101
Evangelista, A., 24:145
Evans, D.G., 24:37
- Fabregat, J., 24:19
Fairfax, M.R., 24:47; 26:35
Fass, R.J., 26:43
Fawson, S., 24:31
Felmingham, D., 25:169
Fenn, J.P., 24:31
Fiore, A., 24:165
Flamm, R., 24:37; 26:73
Fedorko, D.P., 26:47
Fritschel, S.J., 25:1
Fuchs, P.C., 26:23
- Garau, J., 25:205
García, A., 24:19
García-Altozano, J., 24:161
Gates, K.M., 26:69
Gaunt, D.D., 26:149
George, M., 24:141; 26:91
Giger, O., 24:145
Gilchrist, M.J.R., 26:149
Gil-Vernet, S., 24:19
Goldstein, F.W., 25:191
Gomez-Herruz, P., 24:161; 26:137
Gould, J.M., 26:95
Graham, D.Y., 24:37
Granato, C., 25:65
Grüneberg, R.N., 25:169
Guerrier, M.L., 25:191
- Hacek, D.M., 26:117
Hachem, C.Y., 24:37
Haqqie, S.S., 26:91
Harrison, L.H., 24:1
Haugen, T.A., 25:137
Hayat, U., 24:165
Heelan, J.S., 24:65
Heidecker, C.J., 26:95
Herwaldt, L.A., 25:1
Hildred, M.V., 25:113
Hindler, J., 25:137
Hixon, D.L., 24:125; 26:69
Hochstein, L.H., 24:15
Hof, H., 25:117
Hollis, R.J., 25:1, 83; 26:63
Hong, T., 25:21
Hove, M.G.M., 25:97
Howard, W.J., 24:109
Hu, B.-S., 24:81; 26:103
Hu, H.-Y.Y., 24:71
- Jankins, M., 25:133
Johnson, D.M., 24:53; 25:137
Jones, M.F., 26:133
Jones, R.N., 24:53, 87, 109, 113, 155, 169; 25:47, 99, 107, 133, 147, 153, 201; 26:99
Jotte, S., 26:13
- Kapell, K., 25:123
Kashuba, A.D.M., 24:129
Kauffman, C.A., 25:127; 26:17
Khallaf, N., 24:1
Khare, S., 25:101
Kim, K., 24:15
Kimura, G., 24:101
Kinney, J., 26:63
Kish, A., 25:21
Kleemola, M., 26:141
Klepser, M.E., 26:125
Knapp, C.C., 26:29
Kocka, F.E., 24:105
Koontz, F.P., 24:109; 26:149
Korten, V., 26:79
Kretschmar, M., 25:117
Kuntz, P., 25:117
- Lakey, D., 26:13
Lau, Y.-J., 24:81; 26:103
Laverdière, M., 24:61
Leckie, G.W., 24:71
Lee, H.H., 24:71
Lee, J., 26:117
Lemes, M., 25:71
Letourneau, C., 24:65
Lin, Y.-H., 26:103
Lin, Y.-L., 24:81
LiPuma, J.J., 26:95
Liu, P.Y.-F., 24:81; 26:103
Loeffelholz, M.J., 26:149
Lopez-Pizarro, V.M., 24:161
Ludwig, M.D., 26:29
- Marshall, S.A., 24:155
Martín, R., 24:19
Martínez-Beltrán, J., 26:53
Martínez-Lacasa, J.T., 24:19
Martinez-Martinez, J., 24:161
Mastellone, A.J., 24:15
Mecklenburg, F.E., 24:125
Messer, S.A., 25:71
Meyer, P., 25:123
Miller, A., 24:15
Miller, L.A., 26:1
Miller, R.D., 24:7
Millesimo, M., 26:7
Millet, W., 25:21
Millichap, J., 25:15
Mirochnick, M., 24:77
Moellering, R.C., Jr., 25:35
Morris, J.G., Jr., 24:165
Mortensen, J.E., 24:145
Moser, S.A., 24:93
Muldoon, S., 24:71

- Munar, M., 25:143
 Murray, B.E., 26:79

 Ndamuking, J., 25:21
 Neubauer, J.J., 25:1
 Newcomb-Gayman, P., 24:31
 Nichterlein, T., 25:117
 Nishimura, Y., 24:101
 Niubò, J., 24:19
 Nociari, M.M., 25:27
 Noskin, G.A., 25:15; 26:117

 O'Brien, T.F., 25:163
 Olden, D., 25:9
 Ostroff, S.M., 24:1

 Papasian, C.J., 26:63
 Park, C.H., 24:125; 26:69
 Patel, R.C., 24:15
 Péan, Y., 25:191
 Pelton, S.I., 25:195
 Pérez, J.L., 24:19
 Perri, M.B., 25:127
 Peterson, L.R., 25:15; 26:117
 Pfaller, M.A., 24:109; 25:1, 71, 83, 107; 26:63, 125
 Pierce, G., 26:39
 Plouffe, J.F., 25:43
 Pohlman, J.K., 26:29
 Poirier, L., 24:61
 Poland, G.A., 26:133
 Poppiti, Jr., R.J., 25:71
 Postelnick, M., 26:117
 Poupard, J.A., 26:1
 Preston, K.E., 26:91

 Ramer, N., 26:73
 Ramirez, J.A., 24:7
 Ranger-Rogez, S., 24:25
 Rastawicki, W., 26:141
 Rätty, R., 26:141
 Ray, K.A., 24:71
 Reddy, T., 24:37
 Reina, J., 25:143

 Reisberg, B.E., 26:117
 Reves, R.R., 25:113
 Rich, J.D., 24:77
 Ristow, T.A., 25:15
 Rittenhouse, S.F., 26:1
 Roca, J., 24:19
 Rothman, M., 26:109
 Ruprai, D., 24:125

 Sanchez-Atrio, A., 26:137
 Savoia, D., 26:7
 Scardamaglia, M., 24:15
 Schuman, P., 24:47
 Segal, H., 24:31
 Segreti, J., 25:123
 Sharp, S.E., 25:71
 Shi, Z.-Y., 24:81; 26:103
 Shimada, T., 24:101
 Shir, J.-M., 24:81
 Shortridge, V.D., 26:73
 Smith, T.F., 26:133
 Solé, N., 26:137
 Sordelli, D.O., 25:27
 Southern, P.M., Jr., 24:43
 Spearman, P., 26:13
 Sridharan, G., 24:1
 Steinberg, D., 26:109
 Steinhoff, M.C., 24:1
 Stelling, J.M., 25:163
 Stevens, D.A., 26:145
 Stevens, J.A., 26:145
 Stone, B.L., 25:113
 Stosor, V., 26:117
 Stratton, C., 26:13
 Suarez, C.A., 25:71
 Summersgill, J.T., 24:7
 Szuba, M.J., 24:47

 Talbot, G.H., 25:53
 Tanaka, S.K., 24:37; 26:73
 Tesfay, S.S., 24:105
 Tevere, V.J., 24:15
 Thompson, C.J., 26:149

 Thornsberry, C., 25:89
 Tolentino, A., 24:7
 Tomita, K., 24:101
 Tomiyama, H., 25:65
 Torrero, M., 25:27
 Torres, B.B., 25:133
 Toye, B., 25:101
 Tsai, H.-N., 26:103
 Turnidge, J.D., 25:9

 Utrup, L.J., 26:1
 Uzoaru, I., 24:105

 Valdezate, S., 26:53
 Vandel, N.M., 24:125; 26:69
 Vanderhoof, B.H., 25:89
 von Graevenitz, A., 24:121

 Waites, K.B., 24:93
 Wanger, A., 25:201
 Washington, J.A., 25:137, 183; 26:29
 Wasserman, S.S., 24:165
 Weiss, K., 24:61
 Weitzman, S.A., 26:117
 Wendt, C., 25:1
 Wennersten, C.B., 25:35
 Wenzel, R.P., 25:1
 Wilbur, S., 24:65
 Wilke, W.W., 25:107
 Williams, E.C., 26:47
 Wilson, M.L., 25:113
 Win, K.K., 25:21
 Wolfe, E.J., 26:125
 Woods, G.L., 25:97
 Worth, S., 24:87
 Wright, A., 24:165

 Yoder, S.L., 25:53
 Yurack, J., 25:101

 Zarins, L.T., 26:17
 Zervos, M.J., 25:127
 Zucca, M., 26:7

Subject Index to Volumes 24-26

- Abcesses
paraspinal, dapsone and, 24:77-79
biopsy, *Mycobacterium tuberculosis* in, 24:16-17
Nocardia asteroides in, 24:47-51
- Acinetobacter baumannii*
amikacin against, 24:81-85
aminoglycosides against, 24:81-85
amoxicillin against, 24:81-85
amoxicillin/clavulanic acid against, 24:81-85
ampicillin against, 24:81-85
ampicillin/sulbactam against, 24:81-85
 β -lactams against, 24:81-85
cefepime against, 24:81-85
cefotaxime against, 24:81-85
ceftazidime against, 24:81-85
ceftriaxone against, 24:81-85
cefuroxime against, 24:81-85
clavulanic acid against, 24:81-85
gentamicin against, 24:81-85
piperacillin against, 24:81-85
piperacillin/tazobactam against, 24:81-85
sulbactam against, 24:81-85
tazobactam against, 24:81-85
- Acinetobacter* spp., sparfloxacin against, 25:53-64
- Acquired immunodeficiency syndrome (AIDS)
dapson in, 24:77-79
IVIAP test in, 25:65-69
Nocardia asteroides in, 24:47-51
- Acridium ester-labeled DNA probe, for group A *Streptococcus*, 24:65-69
- Acute antibody titers, serum specimens for, 24:7-14
- Acute otitis media, defining resistance and, 25:195-199
- Adenosine triphosphate (ATP), intracellular, *Candida* spp. and, 25:117-121
- Adhesin P1 antibodies, *Mycoplasma pneumoniae*, 26:141-143
- Adrenal insufficiency, *Nocardia asteroides* in, 24:47-51
- Adsorption, of bacteria onto experimental dental plaque, 26:109-115
- Advanced age, pneumococcal osteomyelitis and, 26:137-139
- Aerobic bacteria, lomefloxacin against, 24:16-17
- Aeromonas* spp., sparfloxacin against, 25:53-64
- Agar dilution testing
for *Acinetobacter baumannii*, 24:81-85
for *Haemophilus influenzae*, 24:145-153, 26:95-98
for quinupristin/dalfopristin, 26:99-102
- Agrobacterium radiobacter*. See *Agrobacterium tumefaciens*
- Agrobacterium tumefaciens* (radiobacter), in pregnant woman and stillborn premature fetus, 24:43-45
- AIDS. See Acquired immunodeficiency syndrome
- Alexander Project, study of antimicrobial susceptibility of community-acquired lower respiratory tract pathogens, 25:169-181, 25:183-190
- American Society of Microbiology (ASM) Task Force, on antimicrobial resistance, 25:153-161
- Amikacin, against *Acinetobacter baumannii*, 24:81-85
- Aminoglycosides, against *Acinetobacter baumannii*, 24:81-85
- Amoxicillin
against *Acinetobacter baumannii*, 24:81-85
antimicrobial resistance issues of the future, 25:213-217
defining resistance and, 25:195-199
quality control guidelines for, 24:87-91
- Amoxicillin/clavulanate
antimicrobial resistance issues of the future, 25:213-217
against *Haemophilus influenzae*, 26:95-98
quality control guidelines for, 24:87-91
stability in frozen microdilution PASCO MIC panels, 26:53-61, 53
- Amoxicillin/clavulanic acid
against *Acinetobacter baumannii*, 24:81-85
Alexander Project and, 25:183-190
defining resistance and, 25:195-199
against *Haemophilus influenzae*, 24:145-153
- Amphotericin B
against *Candida albicans* osteomyelitis of zygomatic bone, 24:16-17
against *Candida* (*Torulopsis*) *glabrata*, 25:83-87
- Ampicillin
against *Acinetobacter baumannii*, 24:81-85
against *Enterococcus faecium*, 25:127-131
against *Haemophilus influenzae*, 24:145-153

against *Helicobacter pylori*, 24:37-41
against *Staphylococcus aureus*, 25:107-112
against *Streptococcus pneumoniae*, 25:137-141
- Ampicillin/sulbactam
against *Acinetobacter baumannii*, 24:81-85
against *Staphylococcus aureus*, 25:107-112
Vitek GPS card susceptibility testing accuracy and, 24:109-112
- amplicor *Mycobacterium tuberculosis* test, Roche, 24:15-17
- Anaerobic bacteria, false resistance to metronidazole among, 24:117-119
- Anaerobic bottles, standard, Lytic/F vs., 24:191-196
- Anemia
hemolytic, dapsone-induced, 24:101-103
parvovirus B19 IgG and, 26:133-135
- Antibiotic medium #3, *Candida* spp. and, 26:125-131
- Antibodies
Mycoplasma pneumoniae adhesin P1, 26:141-143
parvovirus B19 IgG and, 26:133-135
Vibrio vulnificus capsular polysaccharide, 24:16-17
- Antifungal panel, dried, evaluation of, 25:77-81
- Antigenemia assay, cytomegalovirus in, 24:19-24
- Antigens
group B streptococcal, 24:125-128
hydatid cyst, 24:205-211
Legionella spp., 24:129-139
- AP-PCR. See Arbitrarily primed polymerase chain reaction
- API20C agar, in *Candida albicans* identification, 24:31-35
- Arbitrarily primed polymerase chain reaction (AP-PCR), for *Pseudomonas aeruginosa*, 24:179-190
- Arthritis, sternoclavicular joint septic, 26:13-15
- Ascites fluid, *Mycobacterium tuberculosis* in, 24:16-17
- ASM. See American Society of Microbiology
- ATP. See Adenosine triphosphate
- Aureobasidium pullulans*, Murex C. *albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- Automated ribotyping system
for *Escherichia coli*, 25:1-8
for *Pseudomonas aeruginosa*, 25:1-8
- Azalides, against *Streptococcus pneumoniae*, 24:113-116
- Azithromycin
against *Neisseria gonorrhoeae* ATCC 49226, 24:87-91
quality control guidelines for, 24:87-91
against *Streptococcus pneumoniae*, 24:113-116
- Azole, fluconazole-resistant *Candida* spp. and, 26:145-148
- Aztreonam
against *Enterobacter cloacae*, 26:29-33
against *Klebsiella pneumoniae*, 26:29-33
against *Pseudomonas aeruginosa*, 26:29-33
against *Serratia marcescens*, 26:29-33
- Bacillus cereus*, glycylicyclines against, 24:53-57
- BacT/Alert blood culture system, CAPD-associated *Penicillium peritonitis* and, 25:101-106
- Bactec 460 TB System, for mycobacteria, 25:113-115
- Bactec 9000 standard/F and Lytic/F blood culture media, clinical comparison of, 24:191-196
- Bactec 9240 blood culture bottles, direct inoculation from, 24:109-112
- Bacteroides thetaiotamicron*, quinupristin-dalfopristin against, 25:147-149

- Baltimore, Maryland, nonmeningitic pneumococcal infection in, 24:1-6
- BamHI, *Pseudomonas aeruginosa* ribotyping and, 25:27-33
- Bartels assay, for *Clostridium difficile* toxin B, 26:47-51
- β -lactam/ β -lactamase inhibitor, oxacillin-resistant *Staphylococcus aureus* and, 24:93-100
- β -lactamase inhibitors, against *Streptococcus pneumoniae*, 25:137-141
- β -lactamases
- Alexander Project and, 25:169-181, 25:183-190
 - French antimicrobial resistance surveillance project and, 25:191-194
 - against *Haemophilus influenzae*, 24:145-153, 26:95-98
- β -lactams
- against *Acinetobacter baumannii*, 24:81-85
 - antimicrobial resistance issues of the future, 25:213-217
 - ciprofloxacin interactions with, 26:29-33
 - French antimicrobial resistance surveillance project and, 25:191-194
 - stability in frozen microdilution PASCO MIC panels, 26:53-61
 - against *Streptococcus pneumoniae*, 25:137-141
- Bilateral adrenal abscesses, *Nocardia asteroides* in, 24:47-51
- Bioluminescence assay, intracellular ATP, *Candida* spp. and, 25:117-121
- bioMerieux Vitek system, *Enterobacteriaceae* and, 25:133-135
- Biopsies
- Mycobacterium tuberculosis* and, 24:16-17
 - U-test for *Helicobacter pylori* and, 24:61-64
- Blastomyces dermatitidis*, localized infection disseminated by surgery, 26:35-37
- BLNAR strains, *Haemophilus influenzae*, 24:145-153
- Blood agar, atypical *Streptococcus pyogenes* growth on, 24:105-107
- Blood cultures
- Agrobacterium tumefaciens* (radiobacter) in, 24:43-45
 - Bactec 460 TB system and, 25:113-115
 - CAPD-associated *Penicillium peritonitis* in, 25:101-106
 - cytomegalovirus in, 24:19-24
 - Gram-positive cocci in, 25:21-25
 - group A *Streptococcus* in, 24:65-69
 - pneumococci in, 24:1-6
 - Septi-Chek bottles and, 24:141-143
 - staphylococci in, 25:107-112
 - Streptococcus pneumoniae* in, 24:113-116
- Bone marrow aspirate, *Mycobacterium tuberculosis* in, 24:16-17
- Bone marrow cultures, Bactec 460 TB system and, 25:113-115
- Bone trauma, pneumococcal osteomyelitis and, 26:137-139
- Bordetella parapertussis*, PCR for, 24:197-200
- Bordetella pertussis*, PCR for, 24:197-200
- Bordetella* spp., sparfloxacin against, 25:53-64
- Brain, *Nocardia asteroides* in, 24:47-51
- Brazil, nonmeningitic pneumococcal infection in, 24:1-6
- Breakpoints
- defining resistance and, 25:195-199
 - fluoroquinolone, 26:23-27
- Broth microdilution testing
- for *Candida* spp., 25:77-81, 26:145-148
 - for *Enterobacteriaceae*, 25:133-135
 - for *Haemophilus influenzae*, 24:145-153
 - for *Helicobacter pylori*, 24:37-41
 - levofloxacin in, 25:43-45
 - sanfetrinem in, 26:39-42
 - for *Staphylococcus aureus*, 25:107-112
- Brucella* spp.
- Septi-Chek blood culture bottles for recovery of, 24:141-143
 - sparfloxacin against, 25:53-64
- BssHII, *Candida* (*Torulopsis*) *glabrata* and, 25:83-87
- Cairo, Egypt, nonmeningitic pneumococcal infection in, 24:1-6
- Campylobacter jejuni*
- ERIC-1 for, 26:103-108
 - polymerase chain reaction for, 26:103-108
 - pulsed-field gel electrophoresis for, 26:103-108
- Campylobacter* spp., sparfloxacin against, 25:53-64
- Candida albicans*
- CHROMagar candida medium for, 24:201-204
 - echinocandin B analog against, 26:125-131
 - fluconazole against, 25:117-112, 26:145-148
 - itraconazole against, 26:145-148
 - ketoconazole against, 26:145-148
 - LY 303366 against, 26:125-131
 - Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:31-35
 - osteomyelitis of zygomatic bone, 24:16-17
- Candida guillermundii*, Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- Candida krusei*
- fluconazole against, 26:117-123
 - molecular typing for, 26:117-123
 - Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:31-35
- Candida lambica*, Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:31-35
- Candida lusitanae*, Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:31-35
- Candida parapsilosis*
- fluconazole against, 26:145-148
 - itraconazole against, 26:145-148
 - ketoconazole against, 26:145-148
 - Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- Candida pseudotropicalis*, Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- Candida* (*Torulopsis*) *glabrata*
- amphotericin B against, 25:83-87
 - CHROMagar candida medium for, 24:201-204
 - echinocandin B analog against, 26:125-131
 - fluconazole against, 25:83-87, 26:145-148
 - fluocytosine against, 25:83-87
 - itraconazole against, 25:83-87, 26:145-148
 - ketoconazole against, 26:145-148
 - LY 303366 against, 26:125-131
 - Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:34-35
 - strain variation in, 25:83-87
- Candida tropicalis*
- CHROMagar candida medium for, 24:201-204
 - echinocandin B analog against, 26:125-131
 - fluconazole against, 26:145-148
 - itraconazole against, 26:145-148
 - ketoconazole against, 26:145-148
 - LY 303366 against, 26:125-131
 - Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- Candida* spp.
- fluconazole against, 25:117-112
 - Sensitre dried antifungal panel for 25:77-81
- CAPD. See Continuous ambulatory peritoneal dialysis
- Capsular polysaccharide, *Vibrio vulnificus*, 24:16-17
- Carbuncle, catalase-negative *Staphylococcus aureus* in, 24:221-223
- Cardiac transplantation, dapsone and, 24:77-79
- Catheters, *Agrobacterium tumefaciens* (radiobacter) in, 24:43-45
- CBTA, CAPD-associated *Penicillium peritonitis* and, 25:101-106
- Cefaclor, against *Haemophilus influenzae*, 24:145-153
- Cefazolin, against *Staphylococcus aureus*, 25:107-112
- Cefepime
- against *Acinetobacter baumannii*, 24:81-85
 - stability in frozen microdilution PASCO MIC panels, 26:53-61
- Cefixime
- Alexander Project and, 25:183-190
 - antimicrobial resistance issues of the future, 25:213-217
 - against *Haemophilus influenzae*, 26:95-98
- Cefotaxime
- against *Acinetobacter baumannii*, 24:81-85
 - against enterococci, 24:213-219
 - against *Escherichia coli*, 24:213-219
 - against *Haemophilus influenzae*, 24:145-153
 - against *Klebsiella* spp., 24:213-219
 - against *Pseudomonas aeruginosa*, 24:213-219
 - against *Stenotrophomonas maltophilia*, 24:213-219
 - against streptococci, 24:213-219

- against *Streptococcus pneumoniae*, 25:89-95, 25:137-141
- Cefpodoxime
antimicrobial resistance issues of the future, 25:213-217
against *Haemophilus influenzae*, 26:95-98
- Cefprozil, against *Haemophilus influenzae*, 26:95-98
- Ceftazidime
against *Acinetobacter baumannii*, 24:81-85
against *Enterobacter cloacae*, 26:29-33
against enterococci, 24:213-219
against *Escherichia coli*, 24:213-219
against *Klebsiella pneumoniae*, 26:29-33
against *Klebsiella* spp., 24:213-219
against *Pseudomonas aeruginosa*, 24:213-219, 26:29-33
against *Serratia marcescens*, 26:29-33
against *Stenotrophomonas maltophilia*, 24:213-219
against streptococci, 24:213-219
against *Streptococcus pneumoniae*, 25:137-141
- Ceftizoxime
against enterococci, 24:213-219
against *Escherichia coli*, 24:213-219
against *Klebsiella* spp., 24:213-219
against *Pseudomonas aeruginosa*, 24:213-219
against *Staphylococcus aureus*, 25:107-112
against *Stenotrophomonas maltophilia*, 24:213-219
against streptococci, 24:213-219
against *Streptococcus pneumoniae*, 25:89-95, 25:137-141
- Ceftriaxone
against *Acinetobacter baumannii*, 24:81-85
Alexander Project and, 25:183-190
defining resistance and, 25:195-199
against enterococci, 24:213-219
against *Escherichia coli*, 24:213-219
against *Haemophilus influenzae*, 24:145-153
against *Klebsiella* spp., 24:213-219
against *Pseudomonas aeruginosa*, 24:213-219
against *Stenotrophomonas maltophilia*, 24:213-219
against streptococci, 24:213-219
against *Streptococcus pneumoniae*, 25:89-95, 25:137-141
- Cefuroxime
against *Acinetobacter baumannii*, 24:81-85
defining resistance and, 25:195-199
against *Haemophilus influenzae*, 24:145-153, 26:95-98
against *Streptococcus pneumoniae*, 25:137-141
- Cellulitis aspirates, *Agrobacterium tumefaciens* (radiobacter) in, 24:43-45
- Central intravenous catheters, *Agrobacterium tumefaciens* (radiobacter) in, 24:43-45
- Centrifugation method, rapid culture, 24:25-29
- Cephalosporins
Alexander Project and, 25:183-190
defining resistance and, 25:195-199
against *Haemophilus influenzae*, 26:95-98
against *Streptococcus pneumoniae*, 26:23-27
- Cephalosporins, broad-spectrum, against *Streptococcus pneumoniae*, 25:137-141
- Cephalosporins, third-generation
against enterococci, 24:213-219
against *Escherichia coli*, 24:213-219
against *Klebsiella* spp., 24:213-219
against *Pseudomonas aeruginosa*, 24:213-219
against *Staphylococcus aureus*, 25:107-112
against *Stenotrophomonas maltophilia*, 24:213-219
against streptococci, 24:213-219
against *Streptococcus pneumoniae*, 25:89-95, 25:137-141
- Cephalothin
against *Staphylococcus aureus*, 25:107-112
Vitek GPS card susceptibility testing accuracy and, 24:109-112
- Cerebrospinal fluid (CSF)
dapsone in, 24:77-79
Mycobacterium tuberculosis in, 24:16-17
- Chemotherapy, against *Isospora belli*, 26:87-89
- Children
adenovirus detection in, 24:25-29
antimicrobial resistance issues of the future, 25:213-217
atypical *Streptococcus pyogenes* discharge from ear, 24:105-107
defining resistance and, 25:195-199
French antimicrobial resistance surveillance project and, 25:191-194
nonmeningitic pneumococcal infection in, 24:1-6
sternoclavicular joint septic arthritis with small-colony variant *Staphylococcus aureus* in, 26:13-15
vertical transmission of *Citrobacter koseri* (*diversus*), 26:63-67
- Chlamydia pneumoniae*
ligase chain reaction DNA amplification assay for, 24:71-76
lower respiratory infection diagnosis of, 24:7-14
- Chlamydia psittaci*, ligase chain reaction DNA amplification assay for, 24:71-76
- Chlamydia* spp., sparfloxacin against, 25:53-64
- Chlamydia trachomatis*, ligase chain reaction DNA amplification assay for, 24:71-76
- Chlamyospore agar, in *Candida albicans* identification, 24:31-35
- Chloramphenicol
Alexander Project and, 25:169-181, 25:183-190
against *Escherichia coli*, 24:173-178
against *Haemophilus influenzae*, 24:145-153
- Chlorhexidine, bacteria adsorbed onto experimental dental plaque and, 26:109-115
- Chocolate agar, atypical *Streptococcus pyogenes* growth on, 24:105-107
- Chocolate Mueller-Hinton agar plates, for *Haemophilus influenzae*, 24:145-153
- Chorioamnionitis, vertical transmission of (*Citrobacter koseri diversus*) and, 26:63-67
- CHROMagar candida medium, for *Candida* spp., 24:201-204
- Chromatography, hydatid cyst antigens and, 24:205-211
- Chronic ambulatory peritoneal dialysis (CAPD)
Penicillium peritonitis and, 25:97-99, 25:101-106
recurrent *Neisseria cinerea* peritonitis and, 26:91-93
- Ciprofloxacin
Alexander Project and, 25:183-190
 β -lactam interactions with, 26:29-33
against *Enterococcus faecalis*, 26:17-21
against *Enterococcus faecium*, 25:127-131, 26:17-21
against Gram-negative bacilli, 25:133-135
against Gram-positive bacteria, 25:35-41
against *Klebsiella pneumoniae*, 25:133-135
against *Serratia marcescens*, 25:133-135
against *Staphylococcus epidermidis*, 26:43-45
against *Streptococcus pneumoniae*, 24:113-116, 26:23-27
Vitek GPS card susceptibility testing accuracy and, 24:109-112
- Citrate utilization, thermosensitive transfer of in *Escherichia coli*, 24:173-178
- Citrobacter diversus*. See *Citrobacter koseri* (*diversus*), transmission of from mother to infant, 26:63-67
- CL-329,998. See DMG-MINO
- CL-331,002. See DMG-DMDOT
- CL-331,928. See DMG-DMDOT
- CL-344,677. See DMG-MINO
- Clarithromycin
Alexander Project and, 25:183-190
against *Helicobacter pylori*, 24:37-41
against *Streptococcus pneumoniae*, 24:113-116
- Clavulanate, against *Streptococcus pneumoniae*, 25:137-141
- Clavulanic acid, against *Acinetobacter baumannii*, 24:81-85
- Clinafloxacin, against *Streptococcus pneumoniae*, 26:23-27
- Clindamycin
defining resistance and, 25:195-199
against *Staphylococcus epidermidis*, 26:43-45
against *Streptococcus pneumoniae*, 25:201-204
- Clonal spread, *Candida krusei* and, 26:117-123
- Clo-Test, for *Helicobacter pylori* in upper gastrointestinal biopsies, 24:61-64
- CMV. See Cytomegalovirus
- Coccarboxylase, in atypical *Streptococcus pyogenes* growth, 24:105-107
- Cocci, glycyclines against, 24:53-57
- Community-acquired pneumonia, management of, 25:205-211
- Community hospital, Shiga-like toxin producing *E. coli* (O157 and non-O157) in, 26:69-72

- Complement fixation antibody, *Mycoplasma pneumoniae* and, 26:141-143
- Concanavalin A column, hydatid cyst antigens and, 24:205-211
- Continuous ambulatory peritoneal dialysis. *See* Chronic ambulatory peritoneal dialysis
- Convalescent antibody titers, serum specimens for, 24:7-14
- Conventional plating, for group B streptococcal antigen from vaginal specimens, 24:125-128
- Corticosteroids, *Candida krusei* and, 26:117-123
- Cotrimoxazole, against *Escherichia coli*, 24:173-178
- CP 99,219. *See* Trovafloxacin
- Cross-resistance
Candida spp. and, 26:145-148
 sparfloxacin and, 25:53-64
Streptococcus pneumoniae and, 24:113-116
Vibrio vulnificus capsular polysaccharide and, 24:16-17
- Cryptococcus laurentii*, Murex C. *albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- Cryptococcus neoformans*, Murex C. *albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- CSF. *See* Cerebrospinal fluid
- Cystic hydatid disease, serologic recognition of antigens in, 24:205-211
- Cytomegalovirus (CMV)
 parvovirus B19 IgG and, 26:133-135
 quantitative antigenemia symptoms, 24:19-24
- Cytotoxin assays, microtiter, for *Clostridium difficile* toxin B, 26:47-51
- Cytotoxi Test, for *Clostridium difficile* toxin B, 26:47-51
- D0870, against *Candida* spp., 25:77-81
- Dapsone
 hemolytic anemia induced by, 24:101-103
 against *Pneumocystis carinii* pneumonia, 24:77-79
 against reactivation cerebral toxoplasmosis, 24:77-79
- DAT. *See* Direct agglutination test
- DBTA, CAPD-associated *Penicillium* peritonitis and, 25:101-106
- Defining resistance, 25:195-199
- Dental plaque, bacteria adsorbed onto experimental, chlorhexidine and, 26:109-115
- Diabetes, *Candida albicans* osteomyelitis of zygomatic bone in, 24:16-17
- Dialysates, culturing of using BacT/Alert system, 25:101-106
- Diarrhea
 adenovirus detection in, 24:25-29
 persistent, *Isospora belli* in, 26:87-89
- DIF. *See* Direct Immunofluorescence assay
- Diphtheroids, glycylicyclines against, 24:53-57
- Direct agglutination test (DAT), for visceral leishmaniasis, 26:7-11
- Direct fluorescent antibody and culture, *Legionella pneumophila*, 24:7-14
- Direct immunofluorescence assay (DIF), for influenza A virus, 25:143-145
- Direct TSA, for group B streptococcal antigen from vaginal specimens, 24:125-128
- Discrepancy testing, for group A *Streptococcus*, 24:65-69
- Disk diffusion susceptibility testing
 azithromycin in, 24:87-91
 cephalosporins in, 24:213-219
 fusidic acid in, 25:9-13
Helicobacter pylori in, 24:37-41
 levofloxacin in, 25:43-45
 lomefloxacin in, 24:16-17
Staphylococcus aureus in, 24:93-100, 25:107-112
Streptococcus pneumoniae in, 25:89-95
 ticarcillin in, 24:87-91
 ticarcillin/clavulanic acid in, 24:87-91
- Disseminated abscesses, *Nocardia asteroides* in, 24:47-51
- DMG-DMDOT (CL-331,002, CL-331,928), against Gram-positive spp., 24:53-57
- DMG-MINO (CL-329,998, CL-344,677), against Gram-positive spp., 24:53-57
- DNA amplification assay
 ligase chain reaction, for *Chlamydia trachomatis*, 24:71-76
 for lower respiratory infection, 24:7-14
- DNA probe, for group A *Streptococcus*, 24:65-69
- Dot-blot enzyme immunoassay (EIA-DB), for influenza A virus, 25:143-145
- Doxycycline, Alexander Project and, 25:169-181, 25:183-190
- Dried antifungal panel, evaluation of, 25:77-81
- DU-6859a, against multiresistant enterococci, 26:79-859
- EagI, *Candida* (*Torulopsis*) *glabrata* and, 25:83-87
- Ear discharge, atypical *Streptococcus pyogenes* from, 24:105-107
- Echinocandin B analog
 against *Candida albicans*, 26:125-131
 against *Candida glabrata*, 26:125-131
 against *Candida tropicalis*, 26:125-131
- Echinococcus granulosus*, hydatid cyst antigens and, 24:205-211
- EcoRI
Candida (*Torulopsis*) *glabrata* and, 25:83-87
Pseudomonas aeruginosa ribotyping and, 25:27-33
- Egypt, nonmeningitic pneumococcal infection in, 24:1-6
- EIA-DB. *See* Dot-blot enzyme immunoassay
- Electrophoresis
 for *Escherichia coli*, 25:1-8
 for hydatid cyst antigen, 24:205-211
 for *Pseudomonas aeruginosa* 25:1-8, 24:179-190
- ELISA. *See* Enzyme linked immunosorbent assay
- Entamoeba histolytica*, metronidazole against, 26:87-89
- Enterobacter cloacae*, ciprofloxacin/ β -lactam combinations against, 26:29-33
- Enterobacteriaceae
 bioMerieux Vitek system and, 25:133-135
 glycylicyclines against, 24:53-57
 modified GNS F6 card and, 25:133-135
 ofloxacin against, 25:133-135
 sparfloxacin against, 25:53-64
- Enterobacterial repetitive intergenic consensus (ERIC-1), for *Campylobacter jejuni*, 26:103-108
- Enterobacter* spp.
 MicroScan Walkaway for, 26:1-6
 Vitek Test for, 26:1-6
- Enterococci
 cefotaxime against, 24:213-219
 ceftazidime against, 24:213-219
 ceftizoxime against, 24:213-219
 ceftriaxone against, 24:213-219
 ciprofloxacin against, 26:17-21
 glycylicyclines against, 24:53-57
 levofloxacin against, 25:35-41
 quinupristin-dalfopristin against, 25:147-149
 sparfloxacin against, 25:53-64
 trovafloxacin against, 26:17-21
- Enterococci, multiresistant, DU-6859a against, 26:79-859
- Enterococcus casseliflavus*, quinupristin-dalfopristin against, 24:59-60
- Enterococcus faecalis*
 ciprofloxacin against, 26:17-21
 E-test for, 25:21-25
 levofloxacin against, 25:35-41
 quinupristin-dalfopristin against, 24:59-60, 25:15-20
 trovafloxacin against, 26:17-21
- Enterococcus faecium*
 ciprofloxacin against, 26:17-21
 E-test for, 25:21-25
 levofloxacin against, 25:35-41
 quinupristin-dalfopristin against, 24:59-60, 25:15-20
 trovafloxacin against, 26:17-21
- Enterococcus faecium*, multidrug-resistant, quinupristin-dalfopristin against, 25:127-131
- Enterococcus faecium*, vancomycin-resistant, glycylicyclines against, 24:53-57
- Enterococcus gallinarum*, quinupristin-dalfopristin against, 24:59-60
- Enterococcus* spp., vancomycin-resistant, quinupristin-dalfopristin combination against, 24:59-60
- Enzyme-linked immunosorbent assay (ELISA)
 in adenovirus isolation, 24:25-29
 hydatid antigens in, 24:205-211
 for *Legionella* urinary antigen, 24:129-139
 for visceral leishmaniasis, 26:7-11
- Epidemiological typing, of *Campylobacter jejuni*, 26:103-108
- Epithelial cells, *Clostridium difficile* toxin B in, 26:47-51
- Epsilometer agar diffusion gradient test, for *Helicobacter pylori*, 24:37-41
- ERIC-1. *See* Enterobacterial repetitive intergenic consensus

- ermAM, macrolide resistance in *Streptococcus pneumoniae* and, 26:73-783
- Erythromycin
against *Staphylococcus epidermidis*, 26:43-45
Streptococcus pneumoniae resistance to, 24:113-116
- Escherichia coli*
cefotaxime against, 24:213-219
ceftazidime against, 24:213-219
ceftizoxime against, 24:213-219
ceftriaxone against, 24:213-219
epidemiological typing of, 25:1-8
MicroScan Walkaway for, 26:1-6
Shiga-like toxin detection, 26:69-72
thermosensitive H₂S-producing Cit+ plasmids from, 24:173-178
Vitek Test for, 26:1-6
- E-Test
false resistance to metronidazole among anaerobic bacteria, 24:117-119
for Gram-positive cocci, 25:21-25
for *Haemophilus influenzae*, 24:145-153
for *Helicobacter pylori*, 24:37-41
for quinupristin/dalfopristin, 26:99-102
for *Staphylococcus aureus*, 24:93-100
for *Streptococcus pneumoniae*, 24:113-116, 25:201-204
- European Union, Alexander Project in, 25:169-181
- Exotoxin A genotyping, *Pseudomonas aeruginosa*, 24:179-190
- Fastidious bacteria, Septi-Chek blood culture bottles for recovery of, 24:141-143
- 5-FC. See 5-Fluorocytosine
- Fetal bovine sera, in *Candida albicans* identification, 24:31-35
- Fetal Clone II, in *Candida albicans* identification, 24:31-35
- Fetus, stillborn, *Agrobacterium tumefaciens* (radiobacter) in, 24:43-45
- Fibroblasts
Clostridium difficile toxin B in 26:47-51
Legionella pneumophila in, 25:123-126
- Fingerprint patterns, PCR, *Campylobacter jejuni* and, 26:103-108
- Fisher's Exact Test, *Clostridium difficile* toxin B and, 26:47-51
- Flagyl. See Metronidazole
- Fleroxacin, against *Streptococcus pneumoniae*, 26:23-27
- Fluconazole
against *Candida albicans*, 25:117-121, 26:145-148
against *Candida albicans* osteomyelitis of zygomatic bone, 24:16-17
against *Candida krusei*, 26:117-123
against *Candida parapsilosis*, 26:145-148
against *Candida* spp., 25:77-81, 25:117-121, 26:145-148
against *Candida* (*Torulopsis*) *glabrata*, 25:83-87, 26:145-148
against *Candida tropicalis*, 26:145-148
Flucytosine, against *Candida* (*Torulopsis*) *glabrata*, 25:83-87
- Fluorochrome technique, for *Mycobacterium tuberculosis*, 24:16-17
- 5-Fluorocytosine (5-FC), against *Candida* spp., 25:77-81
- Fluoroquinolones
Alexander Project and, 25:169-181, 25:183-190
against Gram-negative bacilli, 25:133-135
against *Klebsiella pneumoniae*, 25:133-135
against multiresistant enterococci, 26:79-85
against pneumococci, 26:23-27
against *Serratia marcescens*, 25:133-135
against *Streptococcus pneumoniae*, 26:23-27
- 5-Fluororacil (5-FU) toxicity, in *Candida albicans* osteomyelitis of zygomatic bone, 24:16-17
- Formalin-fixed cytospin slides, cytomegalovirus on, 24:19-24
- France, Alexander Project in, 25:169-181
- Francisella tularensis*, Septi-Chek blood culture bottles for recovery of, 24:141-143
- French antimicrobial resistance surveillance project, highlights of, 25:191-194
- Frozen susceptibility panels, β -lactam stability in, 26:53-61
- Fructosyltransferase, cell-free, chlorhexidine adsorbed onto experimental dental plaque and, 26:109-115
- 5-FU. See 5-Fluororacil
- Fusidic acid, against staphylococci, 25:9-13
- Fusobacterium* spp., quinupristin-dalfopristin against, 25:147-149
- Future, antimicrobial resistance issues of, 25:213-217
- Gamma globulin, parvovirus B19 IgG and, 26:133-135
- Gardnerella* spp., sparfloxacin against, 25:53-64
- Gastric fluid, *Mycobacterium tuberculosis* in, 24:16-17
- Gastroenteritis, adenovirus detection in, 24:25-29
- GC-rich sequence, polymorphic, *Mycobacterium tuberculosis* and, 26:149-151
- Gene-specific primers, macrolide resistance in *Streptococcus pneumoniae* and, 26:73-78
- Genomic DNA
Candida krusei and, 26:117-123
vertical transmission of *Citrobacter koseri* (*diversus*) and, 26:63-67
- Genotyping, *Pseudomonas aeruginosa* ribotyping and, 24:179-190, 25:27-33
- Gen-probe group A *Streptococcus* direct test, throat swabs and, 24:65-69
- Gentamicin
against *Acinetobacter baumannii*, 24:81-85
against *Enterococcus faecium*, 25:127-131
against *Staphylococcus epidermidis*, 26:43-45
- Germ tubes, vs. Murex *C. albicans* CA50 test, 24:31-35
- Glucantim, against visceral leishmaniasis, 26:7-11
- Glucosyltransferase, chlorhexidine adsorbed onto experimental dental plaque and, 26:109-115
- Glycoproteins, hydatid cyst antigens and, 24:205-211
- Glycylcyclines, against Gram-positive spp., 24:53-57
- GNS F6 card, modified, Enterobacteriaceae and, 25:133-135
- Gram-negative spp.
automated ribotyping system for, 25:1-8
 β -lactams against, 26:29-33
cephalosporins against, 24:213-219
ciprofloxacin against, 25:133-135
fluoroquinolones against, 25:133-135
MicroScan Walkaway for, 26:1-6
ofloxacin against, 25:133-135
pulsed-field gel electrophoresis for, 25:1-8
susceptibility discrepancies and, 26:1-6
Vitek Test for, 26:1-6
- Gram-positive spp.
in carbuncle, 24:221-223
ciprofloxacin against, 25:35-41
DMG-DMDOT against, 24:53-57
DMG-MINO against, 24:53-57
E-Test for, 25:21-25
glycylcyclines against, 24:53-57
levofloxacin against, 25:35-41
minocycline against, 24:53-57
ofloxacin against, 25:35-41
d-ofloxacin against, 25:35-41
quinupristin-dalfopristin against, 25:147-149, 26:99-102
sparfloxacin against, 25:35-41
- Grepafloxacin, against *Streptococcus pneumoniae*, 26:23-27
- GV104326. See Sanfetrinem
- HACEK bacilli, Septi-Chek blood culture bottles for recovery of, 24:141-143
- Haemophilus influenzae*
Alexander Project and, 25:169-181, 25:183-190
amoxicillin/clavulanate against, 26:95-98
antimicrobial resistance issues of the future and 25:213-217
cefixime against, 26:95-98
cefpodoxime against, 26:95-98
cefprozil against, 26:95-98
cefuroxime against, 26:95-98
cephalosporins against, 26:95-98
French antimicrobial resistance surveillance project and, 25:191-194
levofloxacin against, 24:155-1505
loracarbef against, 26:95-98
nontypeable susceptibility, 26:95-98
ofloxacin against, 24:155-1505
sanfetrinem against, 26:39-42
susceptibility testing for, 24:145-153
- Haemophilus parainfluenzae*, quinupristin-dalfopristin against, 25:147-149
- Haemophilus* spp.
lomefloxacin against, 24:16-17
sparfloxacin against, 25:53-64
- Haemophilus* test medium, for *Haemophilus influenzae*, 24:145-153
- Hand contact, in *Candida albicans* osteomyelitis of zygomatic bone, 24:16-17

- Heart transplantation, cytomegalovirus in, 24:19-24
- Hektoen enteric agar, and stool cultures for *Shigella* spp., 24:121-124
- Helicobacter pylori*
 ampicillin against, 24:37-41
 broth microdilution for, 24:37-41
 clarithromycin against, 24:37-41
 disk diffusion for, 24:37-41
 metronidazole against, 24:37-41
 U-test for, 24:61-64
- Helicobacter* spp., sparfloxacin against, 25:53-64
- Hematogenous spread, penicillin-intermediate-resistant pneumococcal spondylodiscitis and, 26:137-139
- Hemolytic anemia, dapsone-induced, 24:101-103
- Hensenaspora* spp., Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- Hepatitis, parvovirus B19 IgG and, 26:133-135
- High-performance liquid chromatography (HPLC), dapsone and, 24:77-79
- HindIII*
Candida (Torulopsis) glabrata and, 25:83-87
Pseudomonas aeruginosa ribotyping and, 25:27-33
- Hinfl*
Candida krusei and, 26:117-123
Candida (Torulopsis) glabrata and, 25:83-87
- HIV. See Human immunodeficiency virus
- HIV-1. See Human immunodeficiency virus type 1
- Homosexuals, seronegative, IVIAP test and, 25:65-69
- HPLC. See High-performance liquid chromatography
- HTM broth, for *Haemophilus influenzae*, 24:145-153
- Human immunodeficiency virus (HIV)
Candida albicans osteomyelitis of zygomatous bone with, 24:16-17
Isospora belli and, 26:87-89
Nocardia asteroides in, 24:47-51
 parvovirus B19 IgG and, 26:133-135
- Human immunodeficiency virus type 1 (HIV-1), in vitro induced antibody production test for inconclusive status of, 25:65-69
- Humoral immunity, parvovirus B19 IgG and, 26:133-135
- Hybritech ICON, for group B streptococcal antigen from vaginal specimens, 24:125-128
- Hydatid cyst antigens, serologic recognition of, 24:205-211
- Hydrogen sulfide production, cotransfer of in *Escherichia coli*, 24:173-178
- Hydroxyapatite beads, chlorhexidine adsorbed onto experimental dental plaque and, 26:109-115
- Hyperalimentation, *Candida krusei* and, 26:117-123
- IA-52 monoclonal antibody clone, influenza A virus and 25:143-145
- IFAT. See Indirect immunofluorescence test
- IFN- γ . See Interferon γ
- IIA. See Indirect Immunofluorescent assay
- Imipenem
 against *Enterococcus faecium*, 25:127-131
 against *Staphylococcus aureus*, 25:107-112
 stability in frozen microdilution PASCO MIC panels, 26:53-61
- Immune response, in visceral leishmaniasis, 26:7-11
- Immunoblot assay
 hydatid antigens in, 24:205-211
Mycoplasma pneumoniae adhesin P1 antibodies and, 26:141-143
- Immunocompromised individuals
 adenovirus in, 24:25-29
Agrobacterium tumefaciens (radiobacter) in, 24:43-45
- Immunoglobulin, intravenous, parvovirus B19 IgG in, 26:133-135
- Index of discrimination, for *Pseudomonas aeruginosa* lineage assessment, 24:179-180
- Indirect immunofluorescence test (IFAT), for visceral leishmaniasis, 26:7-11
- Indirect immunofluorescent assay (IIA), for cytomegalovirus, 24:19-24
- Infants, vertical transmission of *Citrobacter koseri (diversus)* and, 26:63-67
- Inflammation, CSF, dapsone and, 24:77-79
- Influenza A virus, respiratory infections caused by, 25:143-145
- Inoculum size, nontypeable *Haemophilus influenzae* susceptibility and, 26:95-98
- Interferon γ (IFN- γ) titration, in visceral leishmaniasis, 26:7-11
- Invertebral disk disease, penicillin-resistant, 26:137-139
- In vitro induced antibody production test (IVIAP) for HIV-1, 25:65-69
- IsoSensitest, of *Streptococcus pneumoniae*, 25:201-204
- Isospora belli*
 pyrimethamine against, 26:87-89
 sulfadiazine against, 26:87-89
- Italy, Alexander Project in, 25:169-181
- Itraconazole
 against *Candida albicans*, 26:145-148
 against *Candida parapsilosis*, 26:145-148
 against *Candida* spp., 25:77-81
 against *Candida (Torulopsis) glabrata*, 25:83-87, 26:145-148
 against *Candida tropicalis*, 26:145-148
- IVIAP. See In vitro induced antibody production test
- JK diphtheroids, glycylicyclines against, 24:53-57
- Kaposi's sarcoma, IVIAP test and, 25:65-69
- Karyotyping, *Candida (Torulopsis) glabrata* and, 25:83-87
- Ketoconazole
 against *Candida albicans*, 26:145-148
 against *Candida parapsilosis*, 26:145-148
 against *Candida (Torulopsis) glabrata*, 26:145-148
 against *Candida tropicalis*, 26:145-148
- Kidney transplantation, cytomegalovirus in, 24:19-24
- Kinyoun acid-fast technique, for *Mycobacterium tuberculosis*, 24:16-17
- Klebsiella pneumoniae*
 bioMerieux Vitek system for, 25:133-135
 ciprofloxacin against, 25:133-135
 ciprofloxacin/ β -lactam combinations against, 26:29-33
 fluoroquinolones against, 25:133-135
 MicroScan Walkaway for, 26:1-6
 modified GNS F6 card for, 25:133-135
 ofloxacin against, 25:133-135
 Vitek Test for, 26:1-6
- Klebsiella* spp.
 cefotaxime against, 24:213-219
 ceftazidime against, 24:213-219
 ceftizoxime against, 24:213-219
 ceftriaxone against, 24:213-219
- Lactobacillus* spp., quinupristin-dalfopristin against, 25:147-149
- Latex agglutination agents, monovalent, 24:1-6
- Legionella pneumophila*
 azithromycin against, 25:123-126
 erythromycin against, 25:123-126
 in lower respiratory infection, 24:7-14
 macrolides against, 25:123-126
- Legionella pneumophila* ATCC 33823
 azithromycin against, 25:123-126
 clarithromycin against, 25:123-126
 erythromycin against, 25:123-126
- Legionella pneumophila* serogroup 1, urinary antigen testing and, 24:129-139
- Legionella* spp.
 quinupristin-dalfopristin against, 25:147-149
 sparfloxacin against, 25:53-64
 urinary antigen testing and, 24:129-139
- Leishmania infantum* promastigotes, in visceral leishmaniasis, 26:7-11
- Leprosy, vertebral osteomyelitis with pleurisy in, 24:101-103
- Leuconostoc* spp., quinupristin-dalfopristin against, 25:147-149
- Leukocytes, cytomegalovirus in, 24:19-24
- Levofloxacin
 against *Enterococcus faecalis*, 25:35-41
 against *Enterococcus faecium*, 25:35-41
 against Gram-positive bacteria, 25:35-41
 against *Haemophilus influenzae*, 24:155-160

- against *Moraxella catarrhalis*, 24:155-160
 against streptococci, 25:35-41, 25:47-51
 against *Streptococcus pneumoniae*, 25:43-45
 Ligase chain reaction DNA amplification assay, for *Chlamydia trachomatis*, 24:71-76
 Lim broth culture method, for group B streptococcal antigen from vaginal specimens, 24:125-128
 Lincosamide, against *Streptococcus pneumoniae*, 25:201-204
 Liver biopsy, *Mycobacterium tuberculosis* in, 24:16-17
 Liver transplantation, cytomegalovirus in, 24:19-24
 Lomefloxacin, multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for, 24:16-17
 Loracarbef, against *Haemophilus influenzae*, 26:95-98
 Lower respiratory tract infections
 Alexander Project and, 25:169-181, 25:183-190
 influenza A virus in, 25:143-145
 PCR on single throat swab specimen and, 24:7-14
 Lungs
 Mycobacterium tuberculosis in, 24:16-17
 Nocardia asteroides in, 24:47-51
 LY 303366
 against *Candida albicans*, 26:125-131
 against *Candida glabrata*, 26:125-131
 against *Candida tropicalis*, 26:125-131
 Lymph node biopsy, *Mycobacterium tuberculosis* in, 24:16-17
 Lysed horse blood, for *Haemophilus influenzae*, 24:145-153
 Lytic/F vs. standard anaerobic bottles, 24:191-196

 MAC. See *Mycobacterium avium* complex
 MacConkey agar, with xylose, and improved specificity for stool cultures for *Shigella* spp., 24:121-124
 Macrolides
 Alexander Project and, 25:169-181, 25:183-190
 antimicrobial resistance issues of the future, 25:213-217
 defining resistance and, 25:195-199
 French antimicrobial resistance surveillance project and, 25:191-194
 against *Legionella pneumophila*, 25:123-126
 against *Streptococcus pneumoniae*, 24:113-116, 25:201-204
 Macrolides-lincosamides-streptogramin B (MLS), *Streptococcus pneumoniae* resistance to, 26:73-78
 Malar ulceration, with zygomatic candidiasis osteomyelitis, 24:16-17
Malassezia furfur, Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:34-35
 Malignancies, *Candida albicans* osteomyelitis of zygomatic bone with, 24:16-17
 MBCs. See Minimum bactericidal concentrations
 MDCK cells, influenza A virus in, 25:143-145
mec gene, *Staphylococcus aureus* and, 24:93-100, 25:107-112
 Meropenem
 stability in frozen microdilution PASCO MIC panels, 26:53-61
 against *Staphylococcus aureus*, 25:107-112
 Methicillin, staphylococcal resistance to, 25:35-41, 25:107-112, 26:17-21
 Metronidazole (Flagyl)
 against *Entamoeba histolytica*, 26:87-89
 false resistance to among anaerobic bacteria, 24:117-119
 against *Helicobacter pylori*, 24:37-41
 Microdilution broth method
 for *Candida (Torulopsis) glabrata*, 25:83-87
 cephalosporins in, 24:213-219
 Micro-Media system, for *Haemophilus influenzae*, 24:145-153
 MicroScan MIC panels, for *Staphylococcus aureus*, 24:93-100
 Microscan system, for *Haemophilus influenzae*, 24:145-153
 MicroScan Walkaway, for Gram-negative bacteria, 26:1-6
 Microtiter cytotoxin assays, for *Clostridium difficile* toxin B, 26:47-51
 MICs. See Minimum inhibitory concentrations
 Minimum bactericidal concentrations (MICs)
 azithromycin, 25:123-126
 clarithromycin, 25:123-126
 erythromycin, 25:123-126
 macrolide, 25:123-126
 Minimum inhibitory concentrations (MICs)
 amikacin, 24:81-85
 aminoglycoside, 24:81-85
 amoxicillin, 24:81-85, 25:213-217
 amoxicillin/clavulanate, 25:213-217, 26:53-61
 amoxicillin/clavulanic acid, 24:81-85
 ampicillin, 24:37-41, 24:81-85, 25:107-112, 25:127-131, 25:137-141
 ampicillin/sulbactam, 24:81-85, 25:107-112
 antimicrobial resistance issues of the future, 25:213-217
 azithromycin, 25:123-126
 aztreonam, 26:29-33
 β -lactam, 24:81-85, 25:137-141, 25:213-217
 β -lactamase inhibitor, 25:137-141
 cefazolin, 25:107-112
 cefepime, 24:81-85, 26:53-61
 cefixime, 25:213-217
 cefotaxime, 24:81-85, 25:89-95, 25:137-141
 cefpodoxime, 25:213-217
 ceftazidime, 24:81-85, 25:137-141, 26:29-33
 ceftizoxime, 25:89-95, 25:107-112, 25:137-141
 ceftriaxone, 24:81-85, 25:89-95, 25:137-141
 cefuroxime, 24:81-85, 25:137-141
 cephalosporin, 25:89-95, 25:107-112, 25:137-141, 26:23-27
 cephalothin, 25:107-112
 chlorhexidine, 26:109-115
 ciprofloxacin, 25:35-41, 25:127-131, 25:133-135, 26:17-21, 26:23-27, 26:43-45
 ciprofloxacin/ β -lactam, 26:29-33
 clarithromycin, 24:37-41, 25:123-126
 clavulanate, 25:137-141
 clavulanic acid, 24:81-85
 clinafloxacin, 26:23-27
 clindamycin, 26:43-45
 D0870, 25:77-81
 DMG-DMDOT, 24:53-57
 DMG-MINO, 24:53-57
 echinocandin B analog 26:125-131
 erythromycin, 25:123-126, 26:43-45
 fleroxacin, 26:23-27
 fluconazole, 25:77-81
 fluoroquinolone, 25:133-135, 26:23-27
 fusidic acid, 25:9-13
 gentamicin, 24:81-85, 25:127-131, 26:43-45
 glycylcycline, 24:53-57
 Gram-positive cocci and, 25:21-25
 grepafloxacin, 26:23-27
 imipenem, 25:107-112, 25:127-131, 26:53-61
 itraconazole, 25:77-81
 levofloxacin, 24:155-160, 25:43-45
 lomefloxacin, 24:16-17
 LY 303366 26:125-131
 macrolide, 25:123-126, 25:213-217
 meropenem, 25:107-112, 26:53-61
 methicillin, 25:107-112
 metronidazole, 24:37-41
 minocycline, 24:53-57
 novobiocin, 25:127-131
 ofloxacin, 24:155-160, 25:35-41, 25:133-135, 26:23-27
 d-ofloxacin, 24:155-160, 25:35-41, 25:213-217
 oxacillin, 24:93-100, 25:89-95, 25:107-112, 26:43-45
 PD131628, 26:23-27
 penicillin, 25:43-45, 25:89-95, 25:107-112
 piperacillin, 24:81-85, 25:137-141
 piperacillin/tazobactam, 24:81-85, 26:29-33, 26:53-61
 quinupristin-dalfopristin, 24:59-60, 25:15-20, 25:127-131, 25:147-149, 26:99-102
 rifampin, 25:127-131
 sanfetrinem, 26:39-42
 sparfloxacin, 25:35-41, 26:23-27
 streptogramin, 26:99-102
 sulbactam, 24:81-85, 25:137-141
 tazobactam, 24:81-85, 25:137-141
 tetracycline, 26:43-45
 ticarcillin, 25:137-141
 ticarcillin/clavulanic acid, 26:29-33
 trimethoprim/sufamethoxazole, 25:213-217, 26:43-45
 trovafloxacin, 26:17-21, 26:23-27
 Minocycline, against Gram-positive spp. 24:53-57
 MLS. See Macrolides-lincosamides-streptogramin B3
 MLS-class drugs, against *Streptococcus pneumoniae*, 25:201-204

- Molecular typing, for *Candida krusei*, 26:117-123
- Monoclonal antibody, against CMV pp65 antigen-24
- Monoclonal antibody clone, influenza A virus and 25:143-145
- Monovalent latex agglutination agents, for diagnosis of nonmeningitic pneumococcal infection, 24:1-6
- MOPS. See Morpholinepropanesulfonic acid
- Moraxella catarrhalis*
Alexander Project and, 25:169-181, 25:183-190
French antimicrobial resistance surveillance project and, 25:191-194
levofloxacin against, 24:155-160
ofloxacin against, 24:155-160
sanfetrinem against, 26:39-42
- Moraxella* spp., sparfloxacin against, 25:53-64
- Morpholinepropanesulfonic acid (MOPS), *Candida* spp. and, 26:125-131
- Mothers, vertical transmission of *Citrobacter koseri* (*diversus*) and, 26:63-67
- MRC-5 human fetal lung fibroblast cells, *Legionella pneumophila* grown in, 25:123-126
- MRSA Crystal ID, for *Staphylococcus aureus*, 24:93-100
- MRSA Screen Agar, for *Staphylococcus aureus*, 24:93-100
- msr A*, macrolide resistance in *Streptococcus pneumoniae* and, 26:73-783
- Mueller-Hinton agar
for *Haemophilus influenzae*, 24:145-153
for *Streptococcus pneumoniae*, 24:113-116
- Mueller-Hinton medium, for *Streptococcus pneumoniae*, 25:201-204
- Muguet plaques, in *Candida albicans* osteomyelitis of zygomatic bone, 24:16-17
- Multidrug resistance, of *Acinetobacter baumannii*, 24:81-85
- Murex *C. albicans* CA50 test, vs. germ tube production for *C. albicans* ID, 24:31-35
- Mycobacteria
for Bactec 460 TB system, 25:113-115
Mycobacteria Growth Indicator Tube for, 25:71-75
Septicheck AFB for, 25:71-75
sparfloxacin against, 25:53-64
- Mycobacteria Growth Indicator tube, vs. Septi-Chek AFB for mycobacteria, 25:71-75
- Mycobacterium avium*
Mycobacteria Growth Indicator Tube for, 25:71-75
Septicheck AFB for, 25:71-75
- Mycobacterium avium* complex (MAC), Roche amplicor PCR test for, 24:15-17
- Mycobacterium fortuitum-chelonae* complex
Mycobacteria Growth Indicator Tube for, 25:71-75
Septicheck AFB for, 25:71-75
- Mycobacterium genavense*, for Bactec 460 TB system, 25:113-115
- Mycobacterium tuberculosis*
Mycobacteria Growth Indicator Tube for, 25:71-75
nonviable isolates, PCR typing of, 26:149-151, 149
Roche amplicor PCR test for, 24:15-17
Septicheck AFB for, 25:71-75
- Mycoplasma pneumoniae*
adhesin P1 antibodies, 26:141-143
in lower respiratory infection, 24:7-14
- Mycoplasma* spp., sparfloxacin against, 25:53-64
- National Committee for Clinical Laboratory Standards (NCCLS), fusidic acid susceptibility testing and, 25:9-13
- National surveillance, of *Streptococcus pneumoniae*, 25:89-95
- NCCLS. See National Committee for Clinical Laboratory Standards
- Neisseria cinerea*, recurrent bacterial peritonitis caused by, 26:91-93
- Neisseria gonorrhoeae* ATCC 49226, azithromycin against, 24:87-91
- Neisseria* spp.
quinupristin-dalfopristin against, 25:147-149
sparfloxacin against, 25:53-64
- Neutropenia, *Candida krusei* and, 26:117-123
- Nontypeable susceptibility, *Haemophilus influenzae*, 26:95-98
- Not I, *Candida* (*Torulopsis*) *glabrata* and, 25:83-87
- Novobiocin, against *Enterococcus faecium*, 25:127-131
- Nucleic acid probe, for group A *Streptococcus*, 24:65-69
- Ofloxacin
Alexander Project and, 25:183-190
against Enterobacteriaceae, 25:133-135
against Gram-negative bacilli, 25:133-135
against Gram-positive bacteria, 25:35-41
against *Haemophilus influenzae*, 24:155-160
against *Klebsiella pneumoniae*, 25:133-135
against *Moraxella catarrhalis*, 24:155-160
against *Pseudomonas aeruginosa*, 25:133-135
against *Serratia marcescens*, 25:133-135
against *Streptococcus pneumoniae*, 24:113-116, 26:23-27
- d-Ofloxacin
against Gram-positive bacteria, 25:35-41
against *Haemophilus influenzae*, 24:155-160
against *Moraxella catarrhalis*, 24:155-160
- OIA. See Optical ImmunoAssay
- Oocysts, *Isospora belli*, 26:87-89
- Open lung biopsy, *Mycobacterium tuberculosis* in, 24:16-17
- Optical ImmunoAssay (OIA), for group B streptococcal antigen from vaginal specimens, 24:125-128
- Oral candidiasis, with zygomatic candidiasis osteomyelitis, 24:16-17
- Oropharynx
Legionella spp. in, 24:7-14
penicillin-intermediate-resistant pneumococcal spondylodiscitis and, 26:137-139
- Osteomyelitis
pneumococcal, 26:137-139
of zygomatic bone, *Candida albicans*, 24:16-17
- Otitis media
and antimicrobial resistance issues of the future, 25:213-217
defining resistance and, 25:195-199
French antimicrobial resistance surveillance project and, 25:191-194
- Overnight microdilution systems, for *Haemophilus influenzae*, 24:145-153
- Oxacillin
Staphylococcus aureus resistance to, 24:93-100, 24:109-112, 25:107-112, 26:43-45
against *Streptococcus pneumoniae*, 25:89-95
Vitek GPS card susceptibility testing accuracy and, 24:109-112
- Oxacillin agar screen plate method, *Staphylococcus aureus* and, 25:107-112
- Oxacillin disk-diffusion test, *Streptococcus pneumoniae* and, 25:89-95
- P1 protein, *Mycoplasma pneumoniae* adhesin P1 antibodies and, 26:141-143
- Paraspinal abscess, dapsone against, 24:77-79
- Parvovirus B19 IgG, in intravenous immunoglobulin samples, 26:133-135
- PASCO frozen microdilution MIC panels, β -lactam stability in, 26:53-61
- PD131628, against *Streptococcus pneumoniae*, 26:23-27
- Pediococcus* spp., quinupristin-dalfopristin against, 25:147-149
- Penicillin
Alexander Project and, 25:169-181, 25:183-190
defining resistance and, 25:195-199
French antimicrobial resistance surveillance project and, 25:191-194
pneumococcal resistance to, 25:205-211
against *Staphylococcus aureus*, 25:107-112
Streptococcus pneumoniae resistance to, 24:113-116, 25:89-95, 25:137-141, 25:201-204, 25:213-217, 26:137-139
- Penicillin-intermediate-resistant pneumococcal spondylodiscitis, *Streptococcus pneumoniae* and, 26:137-139
- Penicillium* peritonitis, continuous ambulatory peritoneal dialysis and, 25:97-99, 25:101-106
- Peptostreptococcus* spp., quinupristin-dalfopristin against, 25:147-149
- Pericardial fluid, *Mycobacterium tuberculosis* in, 24:16-17
- Peripheral blood lymphocytes, in visceral leishmaniasis, 26:7-11
- Peripheral blood mononuclear cells, in HIV-1, IVIAP test and, 25:65-69
- Peritoneal fluid, *Agrobacterium tumefaciens* (*radiobacter*) in, 24:43-45
- Peritonitis
Penicillium, 25:97-99, 25:101-106
recurrent *Neisseria cinerea*, 26:91-93
- PFGE. See Pulsed-field gel electrophoresis

- Pharyngitis, streptococcal, 24:65-69
- Phenotype
 fluconazole-resistant *Candida* spp., 26:145-148
mec A staphylococcal, 25:107-112
 vancomycin, 25:127-131
- Piperacillin
 against *Acinetobacter baumannii*, 24:81-85
 against *Streptococcus pneumoniae*, 25:137-141
- Piperacillin/tazobactam
 against *Acinetobacter baumannii*, 24:81-85
 against *Enterobacter cloacae*, 26:29-33
 against *Klebsiella pneumoniae*, 26:29-33
 against *Pseudomonas aeruginosa*, 26:29-33
 quality control guidelines for, 24:87-91
 against *Serratia marcescens*, 26:29-33
 stability in frozen microdilution PASCO MIC panels, 26:53-61
- Plasmids, in *Escherichia coli* isolate, 24:173-178
- Pleural biopsy, *Mycobacterium tuberculosis* in, 24:16-17
- Pleural effusions, bilateral, vertebral osteomyelitis with, 24:101-103
- Pleural fluid, *Mycobacterium tuberculosis* in, 24:16-17
- Pneumococcal infection, nonmeningitic, 24:1-6
- Pneumococci
 fluoroquinolones against, 26:23-27
 glycyclines against, 24:53-57
 national surveillance of, 25:89-95
 penicillin resistance in, 25:205-211
- Pneumocystis carinii* pneumonia, dapsone against, 24:77-79
- Pneumonia
 community-acquired, 25:205-211
Legionella spp., 24:129-139
Pneumocystis carinii, 24:77-79
- Polyclonal ELISA, for *Legionella* urinary antigen, 24:129-139
- Polymerase chain reaction (PCR)
 for *Bordetella parapertussis*, 24:197-200
 for *Bordetella pertussis*, 24:197-200
 for *Campylobacter jejuni*, 26:103-108
 for *Pseudomonas aeruginosa*, 24:179-190
 IVIAP test and, 25:65-69
 macrolide resistance in *Streptococcus pneumoniae* and, 26:73-783
 nonviable *Mycobacterium tuberculosis* isolates and, 26:149-151
 Roche amplicor, 24:15-17
 on single throat swab specimen, for lower respiratory infection diagnosis, 24:7-14
- Polypeptide bands, hydatid cyst antigens and, 24:205-211
- Polysaccharide, chlorhexidine adsorbed onto experimental dental plaque and, 26:109-115
- Postdetection chemical inactivation method, ligase chain reaction and, 24:71-76
- pp65 antigen, cytomegalovirus, 24:19-24
- Pregnancy
Agrobacterium tumefaciens (radiobacter) in, 24:43-45
 vertical transmission of *citrobacter koseri* (*diversus*) and, 26:63-67
- Prevotella* spp., quinupristin-dalfopristin against, 25:147-149
- Promastigotes, *Leishmania infantum*, 26:7-11
- Proteus mirabilis*
 MicroScan Walkaway for, 26:1-6
 Vitek Test for, 26:1-6
- Protoscoleces, hydatid cyst antigens and, 24:205-211
- Prototheca wickerhamii*, Murex C. *albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- Protozoa, enteric, metronidazole against, 26:87-89
- Pseudomonas aeruginosa*
 cefotaxime against, 24:213-219
 ceftazidime against, 24:213-219
 ceftizoxime against, 24:213-219
 ceftriaxone against, 24:213-219
 ciprofloxacin/ β -lactam combinations against, 26:29-33
 epidemiological typing of, 25:1-8
 lineage assessment of, 24:179-190
 MicroScan Walkaway for, 26:1-6
 ofloxacin against, 25:133-135
 ribotyping and, 25:27-33
 sparfloxacin against, 25:53-64
 Vitek Test for, 26:1-6
- Pulmonary blastomycosis, dissemination of, 26:35-37
- Pulsed-field gel electrophoresis (PFGE)
 for *Campylobacter jejuni*, 26:103-108
 for *Candida* (*Torulopsis*) *glabrata*, 25:83-87
 for *Escherichia coli*, 25:1-8
 for *Pseudomonas aeruginosa*, 25:1-8
 vertical transmission of *citrobacter koseri* (*diversus*) and, 26:63-67
- PvuII, *Pseudomonas aeruginosa* ribotyping and, 25:27-33
- Pyridone carboxylic acid fluoroquinolone derivative, against *Streptococcus pneumoniae*, 24:113-116
- Pyrimethamine, against *Isospora belli*, 26:87-89
- Quality control guidelines, 24:87-91
- Quantitative antigenemia, cytomegalovirus, 24:19-24
- Quinupristin-dalfopristin (RP-59500, Synercid)
 agar dilution test for, 26:99-102
 against *Bacteroides thetaiotamicron*, 25:147-149
 against enterococci, 24:59-60, 25:147-149
 against *Enterococcus faecium*, 25:15-20, 25:127-131
 E-test for, 26:99-102
 against *Fusobacterium* spp., 25:147-149
 against gonococci, 25:147-149
 against Gram-positive spp., 26:99-102
 against *Haemophilus parainfluenzae*, 25:147-149
 against *Lactobacillus* spp., 25:147-149
 against *Legionella* spp., 25:147-149
 against *Leuconostoc* spp., 25:147-149
 against meningococci, 25:147-149
 against *Neisseria* spp., 25:147-149
 against *Pediococcus* spp., 25:147-149
 against *Peptostreptococcus* spp., 25:147-149
 against *Prevotella* spp., 25:147-149
 against staphylococci, 25:147-149
 against streptococci, 25:147-149
 against *Streptococcus bovis*, 25:147-149
- Rapid antigen testing, for group A *Streptococcus* by DNA probe, 24:65-69
- Rapid culture centrifugation method, for adenovirus detection in stools, 24:25-29
- Reactivation cerebral toxoplasmosis, dapsone against, 24:77-79
- Receiver-operator characteristic (ROC) analysis, for ligase chain reaction DNA amplification assay, 24:71-76
- Recurrent bacteremia, *Nocardia asteroides* in, 24:47-51
- Reference agar screen test, *Staphylococcus aureus* and, 25:107-112
- Renal abscess, *Nocardia asteroides* in, 24:47-51
- Restriction endonuclease digests
Candida krusei and, 26:117-123
Candida (*Torulopsis*) *glabrata* and, 25:83-87
- Restriction enzymes
Candida (*Torulopsis*) *glabrata* and, 25:83-87
Pseudomonas aeruginosa and, 24:179-190
- Restriction fragment length polymorphism (RFLP)
Neisseria cinerea, 26:91-93
Pseudomonas aeruginosa, 24:179-190
 vertical transmission of *citrobacter koseri* (*diversus*) and, 26:63-67
- Restriction rDNA profiles, *Pseudomonas aeruginosa* ribotyping and, 25:27-33
- RFLP. See Restriction fragment length polymorphism
- Rhodotorula spp., Murex C. *albicans* CA50 test vs. germ tube production for identification of, 24:33-34
- RiboPrinterTM Microbial Characterization System
 for *Escherichia coli*, 25:1-8
 for *Pseudomonas aeruginosa*, 25:1-8
- Ribosomal operon restriction patterns, *Pseudomonas aeruginosa* ribotyping and, 25:27-33
- Ribosomal RNA (rRNA), *Streptococcus pyogenes*, 24:65-69
- Ribosomes, macrolide resistance in *Streptococcus pneumoniae* and, 26:73-783
- Ribotyping
Escherichia coli, 25:1-8
Pseudomonas aeruginosa, 24:179-190, 25:1-8, 25:27-33
 vertical transmission of *citrobacter koseri* (*diversus*) and, 26:63-67
- Rifampin
 against *Enterococcus faecium*, 25:127-131
 against *Streptococcus pneumoniae*, 25:201-204
- ROC. See Receiver-operator characteristic analysis
- Roche amplicor *Mycobacterium tuberculosis* PCR test, for specimens other than respiratory secretions, 24:15-17

- Roxithromycin, quality control guidelines for, 24:87-91
- RP-59500. See Quinupristin-dalfopristin
- RPMI 1640, *Candida* spp. and, 26:125-131
- rRNA. See Ribosomal RNA
- Saccharomyces cerevisiae*, Murex C. *albicans* CA50 test vs. germ tube production for identification of, 24:34-35
- SaII RFLP analysis, *Pseudomonas aeruginosa*, 24:179-190
- Salmonella newport*, in vertebral osteomyelitis with pleurisy, 24:101-103
- Sanfetrinem (GV104326)
- against *Haemophilus influenzae*, 26:39-42
 - against *Moraxella catarrhalis*, 26:39-42
 - against *Streptococcus pneumoniae*, 26:39-42
- Saõ Paulo, Brazil, nonmeningitic pneumococcal infection in, 24:1-6
- SDS-PAGE. See Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
- Sensitre dried antifungal panel, evaluation of, 25:77-81
- Septic arthritis, with small-colony variant *Staphylococcus aureus*, 26:13-15
- Septi-Chek AFB, vs. MGIT for mycobacteria, 25:71-75
- Septi-Chek blood culture bottles, prolonged incubation of, 24:141-143
- Septic shock, vertical transmission of *Citrobacter koseri* (*diversus*) and, 26:63-67
- Seroconversion, IVIAP test and, 25:65-69
- Serotypes
- adenovirus, 24:25-29
 - Streptococcus pneumoniae*, 25:43-45
- Serratia marcescens*
- bioMerieux Vitek system and, 25:133-135
 - ciprofloxacin against, 25:133-135
 - ciprofloxacin/ β -lactam combinations against, 26:29-33
 - fluoroquinolones against, 25:133-135
 - modified GNS F6 card and, 25:133-135
 - ofloxacin against, 25:133-135
- Serum specimens, for acute and convalescent antibody titers, 24:7-14
- Seventh Day Adventists, *Vibrio vulnificus* exposure in, 24:16-17
- Sfil, *Candida* (*Torulopsis*) *glabrata* and, 25:83-87
- Sheep blood
- group A *Streptococcus* in, 24:65-69
 - Streptococcus pneumoniae* in, 24:113-116
- Sheep blood agar, for group B streptococcal antigen from vaginal specimens, 24:125-128
- Shell-fish industry workers, *Vibrio vulnificus* exposure in, 24:16-17
- Shell vial culture
- cytomegalovirus in, 24:19-24
 - influenza A virus in, 25:143-145
- Shiga-like toxin, producing *Escherichia coli* in a community hospital, 26:69-72
- Shigella* spp., stool cultures for, 24:121-124
- Sickle-cell disease, pneumococcal osteomyelitis and, 26:137-139
- Single culturette throat swabs, group A *Streptococcus* on, 24:65-69
- Skin lesions, *Candida albicans* osteomyelitis of zygomatic bone with, 24:16-17
- Small-colony variants, of *Staphylococcus aureus*, 26:13-15
- Smear examination, for *Mycobacterium tuberculosis*, 24:16-17
- Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), hydatid cyst antigens and, 24:205-211
- Soft tissue lesions, *Candida albicans* osteomyelitis of zygomatic bone with, 24:16-17
- Solid organ transplantation, quantitative CMV antigenemia with symptomatic infection in, 24:19-24
- Spain, Alexander Project in, 25:169-181
- Sparfloxacin
- against Gram-positive bacteria, 25:35-41
 - against *Streptococcus pneumoniae*, 24:113-116, 26:23-27
 - worldwide in vitro literature, 25:53-64
- Spike-back technique, for *Mycobacterium tuberculosis*, 24:16-17
- Spondylodiscitis, penicillin-intermediate-resistant pneumococcal, 26:137-139
- Sputum specimens, of *Mycobacterium tuberculosis*, 24:15-17
- Staphylococci
- fusidic acid against, 25:9-13
 - quinupristin-dalfopristin against, 25:147-149
 - sparfloxacin against, 25:53-64
- Staphylococci, ciprofloxacin-resistant, trovafloxacin against, 26:17-21
- Staphylococci, coagulase-negative
- E-test for, 25:21-25
 - fusidic acid against, 25:9-13
 - mec A* gene phenotype in, 25:107-112
 - Vitek GPS card susceptibility testing accuracy and, 24:109-112
- Staphylococci, *mec A*, phenotypic detection of, 25:107-112
- Staphylococci, oxacillin-resistant
- glycylcyclines against, 24:53-57
 - mec A* gene phenotype in, 25:107-112
- Staphylococci, oxacillin-susceptible, glycylcyclines against, 24:53-57
- Staphylococcus aureus*
- ampicillin against, 25:107-112
 - ampicillin/sulbactam against, 25:107-112
 - cefazolin against, 25:107-112
 - ceftizoxime against, 25:107-112
 - cephalosporins against, 25:107-112
 - cephalothin against, 25:107-112
 - glycylcyclines against, 24:53-57
 - imipenem against, 25:107-112
 - mec A* gene phenotype in, 25:107-112
 - meropenem against, 25:107-112
 - methicillin against, 25:107-112
 - oxacillin against, 25:107-112
 - penicillin against, 25:107-112
 - Vitek GPS card susceptibility testing for, 24:109-112
- Staphylococcus aureus*, catalase-negative, in carbuncle, 24:221-223
- Staphylococcus aureus*, multiresistant, fusidic acid against, 25:9-13
- Staphylococcus aureus*, oxacillin-resistant
- disk diffusion testing for, 24:93-100
 - E-Test for, 24:93-100
 - MicroScan MIC panels for, 24:93-100
 - MRSA Crystal ID for, 24:93-100
 - MRSA Screen Agar for, 24:93-100
- Staphylococcus aureus*, small-colony variant, sternoclavicular joint septic arthritis with, 26:13-15
- Staphylococcus aureus* ATCC 25923
- ticarcillin against, 24:87-91
 - ticarcillin/clavulanic acid against, 24:87-91
- Staphylococcus epidermidis*
- ciprofloxacin against, 26:43-45
 - clindamycin against, 26:43-45
 - erythromycin against, 26:43-45
 - gentamicin against, 26:43-45
 - tetracyclin against, 26:43-45
 - trimethoprim/sulfamethoxazole against, 26:43-45
- Staphylococcus saprophyticus*, fusidic acid against, 25:9-13
- Stenotrophomonas maltophilia*
- cefotaxime against, 24:213-219
 - ceftazidime against, 24:213-219
 - ceftizoxime against, 24:213-219
 - ceftriaxone against, 24:213-219
- Stepwise in vitro exposure, and *Enterococcus faecium* resistance to RP 59500, 25:15-20
- Sternoclavicular joint septic arthritis, with small-colony variant *Staphylococcus aureus*, 26:13-15
- Stillbirth, *Agrobacterium tumefaciens* (radio-bacter) in, 24:43-45
- Stool cultures
- adenovirus in, 24:25-29
 - Clostridium difficile* toxin B in, 26:47-51
 - Isospora belli* in, 26:87-89
 - Shigella* spp. in, 24:121-124
- Streptococci
- cefotaxime against, 24:213-219
 - ceftazidime against, 24:213-219
 - ceftizoxime against, 24:213-219
 - ceftriaxone against, 24:213-219
 - levofloxacin against, 25:35-41, 25:47-51
 - sparfloxacin against, 25:53-64
- Streptococci, β -hemolytic,
- E-test for, 25:21-25
 - glycylcyclines against, 24:53-57
- Streptococci, group A, rapid antigen testing for by DNA probe, 24:65-69
- Streptococci, group B, antigen detection from vaginal specimens, 24:125-128
- Streptococci, methicillin-susceptible, levofloxacin against, 25:35-41
- Streptococci, nutritionally-deficient, Septi-Chek blood culture bottles for recovery of, 24:141-143
- Streptococci, viridans group, E-test for, 21-25
- Streptococcus bovis*, quinupristin-dalfopristin against, 25:147-149
- Streptococcus pneumoniae*
- Alexander Project and, 25:169-181, 25:183-190
 - antimicrobial resistance issues of the future, 25:213-217

- cefotaxime against, 25:89-95
 ceftizoxime against, 25:89-95
 ceftriaxone against, 25:89-95
 cephalosporins against, 26:23-27
 ciprofloxacin against, 26:23-27
 clinafloxacin against, 26:23-27, 24
 defining resistance and, 25:195-199
 E-test for, 25:21-25
 fleroxacin against, 26:23-27
 fluoroquinolones against, 26:23-27
 French antimicrobial resistance surveillance project and, 25:191-194
 grepafloxacin against, 26:23-27
 levofloxacin against, 25:43-45
 macrolides against, 26:73-783
 monovalent latex agglutination reagents for, 24:1-6
 national surveillance of, 25:89-95
 ofloxacin against, 26:23-27
 oxacillin against, 25:89-95
 PD131628 against, 26:23-27
 penicillin against, 25:89-95
 penicillin-intermediate-resistant pneumococcal spondylodiscitis and, 26:137-139
 sanfetrinem against, 26:39-42
 sparfloxacin against, 26:23-27
 third-generation cephalosporins against, 25:89-95
 trovafloxacin against, 26:23-27
Streptococcus pneumoniae, erythromycin-resistant
 clindamycin resistance in, 25:201-204
 sparfloxacin against, 24:113-116
Streptococcus pneumoniae, penicillin-resistant
 ampicillin against, 25:137-141
 β -lactamase inhibitors against, 25:137-141
 β -lactams against, 25:137-141
 cefotaxime against, 25:137-141
 ceftazidime against, 25:137-141
 ceftizoxime against, 25:137-141
 ceftriaxone against, 25:137-141
 cefuroxime against, 25:137-141
 cephalosporins against, 25:137-141
 clavulanate against, 25:137-141
 piperacillin against, 25:137-141
 sulbactam against, 25:137-141
 tazobactam against, 25:137-141
 ticarcillin against, 25:137-141
Streptococcus pyogenes
 atypical, ear discharge due to, 24:105-107
 rRNA of, 24:65-69
Streptococcus sobrinus, chlorhexidine adsorbed onto experimental dental plaque and, 26:109-115
Streptococcus spp., glycylicyclines against, 24:53-57
 Streptogramin
 against *Enterococcus faecium*, 25:15-20
 against Gram-positive spp., 26:99-102
 against *Streptococcus pneumoniae*, 25:201-204
 Streptomycin, against *Escherichia coli*, 24:173-178
 Sulbactam
 against *Acinetobacter baumannii*, 24:81-85
 against *Streptococcus pneumoniae*, 25:137-141
 Sulfadiazine, against *Isospora belli*, 26:87-89
 Sulfomethoxazole
 against *Escherichia coli*, 24:173-178
 Susceptibility discrepancies, 26:1-6
 Synercid. See Quinupristin-dalfopristin
 Synergy studies, of *Enterococcus faecium*, 25:127-131
 Synovial fluid, *Mycobacterium tuberculosis* in, 24:16-17
 Tachyzoites, *Toxoplasma gondii*, dapsone against, 24:77-79
 TAFE. See Transverse alternating field gel electrophoresis
 Taiwan, *Acinetobacter baumannii* clinical isolates from, 24:81-85
 Tazobactam
 against *Acinetobacter baumannii*, 24:81-85
 against *Streptococcus pneumoniae*, 25:137-141
 Tetracycline
 against *Escherichia coli*, 24:173-178
 French antimicrobial resistance surveillance project and, 25:191-194
 against Gram-positive spp., 24:53-57
 against *Staphylococcus epidermidis*, 26:43-45
 Thermosensitive transfer, in *Escherichia coli* isolate, 24:173-178
 Thoracotomy, dissemination of pulmonary blastomycosis after, 26:35-37
 Throat swab specimens
 group A *Streptococcus* on, 24:65-69
 single, using PCR on, 24:7-14
³H-Thymidine, chlorhexidine adsorbed onto experimental dental plaque and, 26:109-115
 Ticarcillin
 quality control guidelines for, 24:87-91
 against *Staphylococcus aureus* ATCC 25923, 24:87-91
 against *Streptococcus pneumoniae*, 25:137-141
 Ticarcillin/clavulanate, quality control guidelines for, 24:87-91
 Ticarcillin/clavulanic acid
 against *Enterobacter cloacae*, 26:29-33
 against *Klebsiella pneumoniae*, 26:29-33
 against *Pseudomonas aeruginosa*, 26:29-33
 against *Serratia marcescens*, 26:29-33
 against *Staphylococcus aureus* ATCC 25923, 24:87-91
 Timed killing kinetic studies, of ciprofloxacin/ β -interactions, 26:29-33
 Time-kill studies, of *Enterococcus faecium*, 25:127-131
Torulopsis glabrata. See *Candida glabrata*
Toxoplasma gondii, dapsone against, 24:77-79
 Toxoplasmosis, reactivation cerebral, 24:77-79
 Transbronchial biopsy, *Mycobacterium tuberculosis* in, 24:16-17
 Transconjugants, in *Escherichia coli* isolate, 24:173-178
 Transplantation
 dapsone and, 24:77-79
 solid organ, 24:19-24
 Transverse alternating field gel electrophoresis (TAFE), for *Pseudomonas aeruginosa*, 24:179-190
Trichosporon beigelii, Murex C. *albicans* CA50 test vs. germ tube production for identification of, 24:34-35
 Trimethoprim, against *Escherichia coli*, 24:173-178
 Trimethoprim/sulfamethoxazole
 Alexander Project and, 25:169-181, 25:183-190
 antimicrobial resistance issues of the future, 25:213-217
 defining resistance and, 25:195-199
 against *Escherichia coli*, 24:173-178
 French antimicrobial resistance surveillance project and, 25:191-194
 against *Haemophilus influenzae*, 24:145-153
 against *Staphylococcus epidermidis*, 26:43-45
 against *Streptococcus pneumoniae*, 25:201-204
 Vitek GPS card susceptibility testing accuracy and, 24:109-112
 Trovafloxacin (CP 99,219)
 against *Enterococcus faecalis*, 26:17-21
 against *Enterococcus faecium*, 26:17-21
 quality control guidelines for, 24:87-91
 against *Streptococcus pneumoniae*, 26:23-27
 Trypticase soy agar plates, group A *Streptococcus* on, 24:65-69
 Tube culture
 in adenovirus isolation, 24:25-29
 cytomegalovirus in, 24:19-24
 Tuberculosis, clinical diagnosis of, 24:16-17
 12B bottles, processed on Bactec 460 TB system, 25:113-115
 U-100592, quality control guidelines for, 24:87-91
 U-100766, quality control guidelines for, 24:87-91
 Ulcer biopsy, *Mycobacterium tuberculosis* in, 24:16-17
 United States
 Alexander Project in, 25:169-181, 25:183-190
 nonmeningitic pneumococcal infection in, 24:1-6
 Upper gastrointestinal biopsies, U-test for *Helicobacter pylori* in, 24:61-64
 Upper respiratory tract infections
 French antimicrobial resistance surveillance project and, 25:191-194
 recurrent *Neisseria cinerea* peritonitis and, 26:91-93
 Urea broth-based test, for *Helicobacter pylori* in upper gastrointestinal biopsies, 24:61-64
 Ureaplasma spp., sparfloxacin against, 25:53-64
 3H-Uridine, chlorhexidine adsorbed onto experimental dental plaque and, 26:109-115
 Urinary antigen, *Legionella* spp., 24:129-139
 Urinary tract infections
Agrobacterium tumefaciens (radiobacter) in, 24:43-45
Chlamydia trachomatis in, 24:71-76

- Escherichia coli* in, 24:173-178
- Urine specimen, for *Legionella pneumophila* serogroup 1 antigen detection, 24:7-14
- U-Test, for *Helicobacter pylori* in upper gastrointestinal biopsies, 24:61-64
- Vaginal specimens, group B streptococcal antigen in, 24:125-128
- Vancomycin
 enterococcal resistance to, 24:53-57, 25:35-41
 against *Enterococcus faecium*, 24:53-57, 25:127-131
- Vertebral disk disease, penicillin-resistant, 26:137-139
- Vertebral osteomyelitis with pleurisy, 24:101-103
- Vertical transmission, *Citrobacter koseri* (diversus), 26:63-67
- Vibrio vulnificus*, antibodies reacting with capsular polysaccharide of, 24:16-17
- Visceral leishmaniasis, immune response evaluation in, 26:7-11
- Vitek Haemophilus susceptibility cards, for *Haemophilus influenzae*, 24:145-153
- Vitek GPS card susceptibility testing, using direct inoculation from Bactec 9240 blood culture bottles, 24:109-112
- Vitek system
 Enterobacteriaceae and, 25:133-135
 for Gram-negative spp., 26:1-6
- Western immunoblot assay, hydatid antigens in, 24:205-211
- WHONET, in removing obstacles to full use of information about antimicrobial resistance, 25:163-168
- XTT, intracellular ATP, *Candida* spp. and, 25:117-121
- Xylose, MacConkey agar with, and stool cultures for *Shigella* spp., 24:121-124
- Xylose-lysine-desoxycholate agar, and stool cultures for *Shigella* spp., 24:121-124
- Yeast
 Murex *C. albicans* CA50 test vs. germ tube production for identification of, 24:31-35
- Zygomatic bone, *Candida albicans* osteomyelitis of, 24:16-17

UNITED STATES POSTAL SERVICE		Statement of Ownership, Management, and Circulation (Required by 39 USC 3685)	
1. Publication Title Diagnostic Microbiology and Infectious Disease		2. Publication Number 742-730	3. Filing Date 10/01/96
4. Issue Frequency Monthly		5. Number of Issues Published Annually 12	6. Annual Subscription Price \$640 Inst
7. Complete Mailing Address of Known Office of Publication (Not printer) (Street, city, county, state, and ZIP+4)		Contact Person Mary Linser	
Elsevier Science Inc. 655 Avenue of the Americas, NY, NY 10010-5107		Telephone 212-633-3818	
8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not printer) Elsevier Science Inc. 655 Avenue of the Americas, NY, NY 10010-5107			
9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not leave blank)			
Publisher (Name and complete mailing address) Elsevier Science Inc. 655 Avenue of the Americas, NY, NY 10010-5107			
Editor (Name and complete mailing address) Ronald N. Jones, MD, Professor of Pathology, University of IA Hospitals, Iowa City, IA 52242			
Managing Editor (Name and complete mailing address) Tina Bonanno, Elsevier Science Inc., 600 White Plains Road, Tarrytown, NY 10591			
10. Owner (Do not leave blank. If the publication is owned by a corporation, give the name and address of the corporation immediately followed by the names and addresses of all stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, give the names and addresses of the individual owners. If owned by a partnership or other unincorporated firm, give its name and address as well as those of each individual owner. If the publication is published by a nonprofit organization, give its name and address.)			
Full Name		Complete Mailing Address	
Elsevier Science Inc.		655 Avenue of the Americas	
		New York NY 10010-5107	
11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box <input checked="" type="checkbox"/> None			
Full Name		Complete Mailing Address	
wholly owned subsidiary of		4520 East-West Highway	
Reed/Elsevier US Holdings		Bethesda, MD 20814	
12. Tax Status (For completion by nonprofit organizations authorized to mail at special rates) (Check one) <input type="checkbox"/> The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes: <input type="checkbox"/> Has Not Changed During Preceding 12 Months <input type="checkbox"/> Has Changed During Preceding 12 Months (Publisher must submit explanation of change with this statement)			
13. Publication Title Diagnostic Microbiology and Infectious Disease		14. Issue Date for Circulation Data Below Vol 25, # 2, Aug 1996	
15. Extent and Nature of Circulation		Average No. Copies Each Issue During Preceding 12 Months	Actual No. Copies of Single Issue Published Nearest to Filing Date
a. Total Number of Copies (Net press run)		1,024	793
b. Paid and/or Requested Circulation			
(1) Sales Through Dealers and Carriers, Street Vendors, and Counter Sales (Not mailed)		0	0
(2) Paid or Requested Mail Subscriptions (Include advertiser's proof copies and exchange copies)		668	501
c. Total Paid and/or Requested Circulation (Sum of 15b(1) and 15b(2))		668	501
d. Free Distribution by Mail (Samples, complimentary, and other free)		207	202
e. Free Distribution Outside the Mail (Carriers or other means)		0	0
f. Total Free Distribution (Sum of 15d and 15e)		207	202
g. Total Distribution (Sum of 15c and 15f)		875	703
h. Copies not Distributed			
(1) Office Use, Leftovers, Spoiled		317	90
(2) Returns from News Agents		0	0
i. Total (Sum of 15g, 15h(1), and 15h(2))		1,024	793
Percent Paid and/or Requested Circulation (15c / 15g x 100)		94.48%	71.27%
16. Publication of Statement of Ownership <input checked="" type="checkbox"/> Publication required. Will be printed in the Vol. 26, No. 3 issue of this publication. <input type="checkbox"/> Publication not required. November 1996			
17. Signature and Title of Editor, Publisher, Business Manager, or Owner John O. Bailey		Director of Marketing	Date 10/1/96
I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including multiple damages and civil penalties).			

